TLSA — Tiziana Life Sciences Share News
0.000.00%
Last trade - 00:00- $115.83m
- $113.58m
Brief: Tiziana Life Sciences - Submits Request To FDA For Orphan Drug Designation For Intranasal Foralumab For Msa
Brief: Tiziana Announces Last Patient Completes Last Visit In Phase 2A Inform-MS Trial Of Intranasal Foralumab
Brief: Tiziana Announces Last Patient Successfully Dosed In Its Phase 2 Inform-MS Trial
Brief: Tiziana Announces New Positive Clinical Data For Intranasal Foralumab In Non-Active Secondary Progressive Multiple Sclerosis
U.S. STOCKS ON THE MOVE -Viatris, Clear Secure, Bicara
U.S. STOCKS ON THE MOVE-Sharps Technology, Whirlpool, Applovin
U.S. STOCKS ON THE MOVE-Oracle, Vanda, Keysight
Tiziana Life Sciences rises as nasal MS drug shows promise in early study
Brief: Tiziana Life Sciences Doses First Patient In Phase 2 Alzheimer’S Clinical Trial
Brief: Tiziana Life Sciences Announces Withdrawal Of Proposed Public Offering
Brief: Aquestive Therapeutics Announces Leadership Expansion To Support Growth
Brief: Department Of Defense Awards Grant To Advance Tiziana’s Intranasal Anti-CD3 Therapy for Treating Spinal Cord Injury
Brief: Tiziana Life Sciences Executive Chairman Gabriele Cerrone Purchased 15,000 Common Shares At $1.55 Per Share
Brief: Tiziana Life Sciences Announces University of Massachusetts Starts Dosing Intranasal Foralumab in Phase 2 Multiple Sclerosis Trial
Brief: Tiziana Life Sciences Announces Johns Hopkins University Commences Dosing Nasal Foralumab In Phase 2 Multiple Sclerosis Clinical Trial
Brief: Tiziana Life Sciences Ltd Files For Mixed Shelf Of Up To $250 Million - SEC Filing
Brief: Tiziana Life Sciences Files Investigational New Drug Application With FDA For ALS Phase 2 Clinical Trial
Brief: Tiziana Life Sciences Announces Agreement With Renaissance Lakewood
Brief: Tiziana Life Sciences Announces Agreement For Product Development Services With Renaissance Lakewood, Llc